AU2014236370C1 - 5-bromo-indirubins - Google Patents
5-bromo-indirubins Download PDFInfo
- Publication number
- AU2014236370C1 AU2014236370C1 AU2014236370A AU2014236370A AU2014236370C1 AU 2014236370 C1 AU2014236370 C1 AU 2014236370C1 AU 2014236370 A AU2014236370 A AU 2014236370A AU 2014236370 A AU2014236370 A AU 2014236370A AU 2014236370 C1 AU2014236370 C1 AU 2014236370C1
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- unsubstituted
- compound
- heterocycloalkyl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- GBBXKOBBZZLXKO-NXGRKYSHSA-N CC1NCCN(CCO/N=C(\c2ccccc2N2)/C2=C(\c(cc(cc2)Br)c2N2)/C2=O)C1 Chemical compound CC1NCCN(CCO/N=C(\c2ccccc2N2)/C2=C(\c(cc(cc2)Br)c2N2)/C2=O)C1 GBBXKOBBZZLXKO-NXGRKYSHSA-N 0.000 description 2
- 0 *c(cc1C2=NOI*)c(*)cc1NC2=C(c(cc(cc1)Br)c1N1)C1=O Chemical compound *c(cc1C2=NOI*)c(*)cc1NC2=C(c(cc(cc1)Br)c1N1)C1=O 0.000 description 1
- HSWLLGOTCHPELQ-HLDOLBPXSA-N CN(CCO/N=C(\c1ccccc1N1)/C1=C(\c(cc(cc1)Br)c1N1)/C1=O)C1CCN(C)CC1 Chemical compound CN(CCO/N=C(\c1ccccc1N1)/C1=C(\c(cc(cc1)Br)c1N1)/C1=O)C1CCN(C)CC1 HSWLLGOTCHPELQ-HLDOLBPXSA-N 0.000 description 1
- IYEDJSCYLQZJNI-YVJMXYSRSA-N CN(CCO/N=C(\c1ccccc1N1)/C1=C(\c(cc(cc1)Br)c1N1)/C1=O)Cc1ncccc1 Chemical compound CN(CCO/N=C(\c1ccccc1N1)/C1=C(\c(cc(cc1)Br)c1N1)/C1=O)Cc1ncccc1 IYEDJSCYLQZJNI-YVJMXYSRSA-N 0.000 description 1
- HSWLLGOTCHPELQ-UHFFFAOYSA-O CN(CCON=C(c1ccccc1N1)C1=C(c(cc(cc1)Br)c1N1)C1=O)C1CC[NH+](C)CC1 Chemical compound CN(CCON=C(c1ccccc1N1)C1=C(c(cc(cc1)Br)c1N1)C1=O)C1CC[NH+](C)CC1 HSWLLGOTCHPELQ-UHFFFAOYSA-O 0.000 description 1
- IYEDJSCYLQZJNI-UHFFFAOYSA-O C[NH+](CCON=C(c1ccccc1N1)C1=C(c(cc(cc1)Br)c1N1)C1=O)Cc1ncccc1 Chemical compound C[NH+](CCON=C(c1ccccc1N1)C1=C(c(cc(cc1)Br)c1N1)C1=O)Cc1ncccc1 IYEDJSCYLQZJNI-UHFFFAOYSA-O 0.000 description 1
- GHYWPXBBKKPEHX-HBLARLPJSA-N O=C1Nc(ccc(Br)c2)c2/C1=C1/Nc2ccccc2/C1=N\OCCCN(C(c1c2cccc1)=O)C2=O Chemical compound O=C1Nc(ccc(Br)c2)c2/C1=C1/Nc2ccccc2/C1=N\OCCCN(C(c1c2cccc1)=O)C2=O GHYWPXBBKKPEHX-HBLARLPJSA-N 0.000 description 1
- HIFOXQJVTGTKFN-IVGNLCKYSA-N O=C1Nc(ccc(Br)c2)c2/C1=C1/Nc2ccccc2/C1=N\OCCN1CCNCC1 Chemical compound O=C1Nc(ccc(Br)c2)c2/C1=C1/Nc2ccccc2/C1=N\OCCN1CCNCC1 HIFOXQJVTGTKFN-IVGNLCKYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783290P | 2013-03-14 | 2013-03-14 | |
| US61/783,290 | 2013-03-14 | ||
| PCT/US2014/028730 WO2014153023A1 (en) | 2013-03-14 | 2014-03-14 | 5-bromo-indirubins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2014236370A1 AU2014236370A1 (en) | 2015-09-17 |
| AU2014236370B2 AU2014236370B2 (en) | 2018-07-19 |
| AU2014236370C1 true AU2014236370C1 (en) | 2019-01-17 |
Family
ID=51581389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014236370A Ceased AU2014236370C1 (en) | 2013-03-14 | 2014-03-14 | 5-bromo-indirubins |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20160068517A1 (enExample) |
| EP (1) | EP2970310B1 (enExample) |
| JP (1) | JP6422936B2 (enExample) |
| KR (1) | KR102275112B1 (enExample) |
| CN (1) | CN105283456B (enExample) |
| AU (1) | AU2014236370C1 (enExample) |
| BR (1) | BR112015023383A2 (enExample) |
| CA (1) | CA2902914A1 (enExample) |
| EA (1) | EA035877B1 (enExample) |
| IL (1) | IL240916A0 (enExample) |
| MX (1) | MX2015013021A (enExample) |
| WO (1) | WO2014153023A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015013021A (es) | 2013-03-14 | 2016-07-14 | Nat And Kapodistrian University Of Athens | 5-bromo-indirrubinas. |
| US20150259288A1 (en) | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
| CN114224907A (zh) | 2015-07-02 | 2022-03-25 | 希望之城 | 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 |
| AU2018358582B2 (en) * | 2017-10-31 | 2021-06-10 | Pelemed Co., Ltd. | Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer |
| KR102443617B1 (ko) * | 2019-12-06 | 2022-09-16 | 광주과학기술원 | 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물 |
| KR102744517B1 (ko) * | 2022-02-14 | 2024-12-19 | 주식회사 펠레메드 | 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005107466A1 (en) * | 2004-05-12 | 2005-11-17 | Bayer Cropscience Gmbh | Plant growth regulation |
| WO2007099402A2 (en) * | 2005-12-23 | 2007-09-07 | Centre National De La Recherche Scientifique (Cnrs) | New 3’-, 7-substituted indirubins and their applications |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| FR2801216A1 (fr) * | 1999-11-23 | 2001-05-25 | Centre Nat Rech Scient | Utilisation de derives d'indirubine pour la fabrication de medicaments |
| US20050154046A1 (en) | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| US20060078494A1 (en) * | 2004-09-24 | 2006-04-13 | Sapphire Therapeutics, Inc. | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| ATE529402T1 (de) * | 2008-08-01 | 2011-11-15 | Centre Nat Rech Scient | 3',6-substituierte indirubine und ihre biologischen anwendungen |
| EP2518139A1 (en) * | 2011-04-27 | 2012-10-31 | Universitätsklinikum Jena | Use of indirubin derivatives for producing pluripotent stem cells |
| EP2733140A4 (en) | 2011-07-15 | 2014-11-26 | Univ Nihon | INDIRUBINE DERIVATIVE WITH HIGHLY SELF-ACTIVE CYTOTOXICITY FOR POOR TUMORS |
| US10435367B2 (en) * | 2013-03-14 | 2019-10-08 | City Of Hope | Indirubin derivatives, and uses thereof |
| MX2015013021A (es) * | 2013-03-14 | 2016-07-14 | Nat And Kapodistrian University Of Athens | 5-bromo-indirrubinas. |
| US20150259288A1 (en) | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
-
2014
- 2014-03-14 MX MX2015013021A patent/MX2015013021A/es unknown
- 2014-03-14 CN CN201480021350.4A patent/CN105283456B/zh active Active
- 2014-03-14 BR BR112015023383A patent/BR112015023383A2/pt not_active Application Discontinuation
- 2014-03-14 WO PCT/US2014/028730 patent/WO2014153023A1/en not_active Ceased
- 2014-03-14 EP EP14770647.7A patent/EP2970310B1/en active Active
- 2014-03-14 KR KR1020157027506A patent/KR102275112B1/ko not_active Expired - Fee Related
- 2014-03-14 CA CA2902914A patent/CA2902914A1/en not_active Abandoned
- 2014-03-14 AU AU2014236370A patent/AU2014236370C1/en not_active Ceased
- 2014-03-14 JP JP2016502881A patent/JP6422936B2/ja not_active Expired - Fee Related
- 2014-03-14 EA EA201591709A patent/EA035877B1/ru not_active IP Right Cessation
-
2015
- 2015-08-30 IL IL240916A patent/IL240916A0/en unknown
- 2015-09-10 US US14/850,579 patent/US20160068517A1/en not_active Abandoned
-
2018
- 2018-02-15 US US15/898,151 patent/US20180170915A1/en not_active Abandoned
-
2020
- 2020-02-13 US US16/790,611 patent/US11306072B2/en active Active
-
2022
- 2022-03-09 US US17/690,323 patent/US20220274964A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005107466A1 (en) * | 2004-05-12 | 2005-11-17 | Bayer Cropscience Gmbh | Plant growth regulation |
| WO2007099402A2 (en) * | 2005-12-23 | 2007-09-07 | Centre National De La Recherche Scientifique (Cnrs) | New 3’-, 7-substituted indirubins and their applications |
Non-Patent Citations (4)
| Title |
|---|
| BEAUCHARD, A. et al, Bioorganic & Medicinal Chemistry, 2006, vol. 14, pages 6434-6443 * |
| GINZINGER, W. et al, CHEMISTRY & BIODIVERSITY, 2012, vol. 9, pages 2175 - 2185 * |
| OLIVIER, D. et al, PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES, 2008, vol. 7, pages 328 - 336 * |
| VOUGOGIANNOPOULOU, K. et al, JOURNAL OF MEDICINAL CHEMISTRY, 2008, vol. 51, pages 6421 - 6431 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20180170915A1 (en) | 2018-06-21 |
| CN105283456B (zh) | 2018-12-18 |
| IL240916A0 (en) | 2015-10-29 |
| US11306072B2 (en) | 2022-04-19 |
| EP2970310A1 (en) | 2016-01-20 |
| MX2015013021A (es) | 2016-07-14 |
| CA2902914A1 (en) | 2014-09-25 |
| BR112015023383A2 (pt) | 2017-07-18 |
| KR20160006669A (ko) | 2016-01-19 |
| JP6422936B2 (ja) | 2018-11-14 |
| US20220274964A1 (en) | 2022-09-01 |
| HK1220197A1 (zh) | 2017-04-28 |
| KR102275112B1 (ko) | 2021-07-08 |
| WO2014153023A1 (en) | 2014-09-25 |
| EP2970310A4 (en) | 2016-09-07 |
| JP2016514160A (ja) | 2016-05-19 |
| US20200283421A1 (en) | 2020-09-10 |
| US20160068517A1 (en) | 2016-03-10 |
| EA201591709A1 (ru) | 2016-03-31 |
| EP2970310B1 (en) | 2020-11-11 |
| AU2014236370A1 (en) | 2015-09-17 |
| EA035877B1 (ru) | 2020-08-25 |
| CN105283456A (zh) | 2016-01-27 |
| AU2014236370B2 (en) | 2018-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11964941B2 (en) | 5-Bromo-indirubins | |
| US11730736B2 (en) | Anticancer agents | |
| US20220274964A1 (en) | 5-bromo-indirubins | |
| US12398151B2 (en) | Sumo inhibitor compounds and uses thereof | |
| US12325691B2 (en) | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | |
| WO2013188452A1 (en) | Compounds and methods of treating cancer | |
| WO2017190107A1 (en) | Sigma receptor binders | |
| US20230127630A1 (en) | Igf2bp2 inhibitors and uses thereof | |
| US20220274929A1 (en) | Thiosemicarbazone compounds and uses thereof | |
| AU2021217665A1 (en) | Elongation Factor 1-alpha inhibitors and uses thereof | |
| US11213510B2 (en) | Thioindirubins | |
| US20230114304A1 (en) | Depalmitoylating compositions and the use thereof | |
| WO2021237111A1 (en) | Notch inhibitors and uses thereof | |
| HK1220197B (en) | 5-bromo-indirubins | |
| US20230203003A1 (en) | Notch Inhibitors and Uses Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 OCT 2018 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 04 OCT 2018 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |